Estrogen receptor (ER) status
![Case Study of Infiltrating Carcinoma of the Breast in Correlation with the Incidence of the Estrogen Receptor [ER], Progesteron Receptor [PR] and HER2nue Status](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==)
Case Study of Infiltrating Carcinoma of the Breast in Correlation with the Incidence of the Estrogen Receptor [ER], Progesteron Receptor [PR] and HER2nue Status
... for receptor study is sent at low temperature in ice ...called estrogen receptor positive ...usually estrogen receptor positive and premenopausal cases are 30% positive ...of ...
5
Tamoxifen may prevent both ER+ and ER breast cancers and select for ER carcinogenesis: an alternative hypothesis
... the ER+ or ER- second primary cancers conditional on the estrogen receptor (ER) status of the first breast primary from long term follow-up of the 5,513 patients from NSABP ...
6
Clinical features of brain metastases in breast cancer: an implication for hippocampal-sparing whole-brain radiation therapy
... menopausal status, local treatment, tumor–node–metastasis (TNM) stage, estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor ...
5
Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women
... of ER concentrations in breast cancer tissue is an established method of predicting the response of a tumor to endocrine therapy, either using the traditional radioligand binding assay, or the more recent IHC ...
7
Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype
... in ER+ breast cancer could be used to identify a patient subset most likely to benefit from hormonal therapy ...both ER+/PR+ and ER+/PR- patients show significant benefit from tamoxifen therapy, and ...
13
Original Article Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features
... menopausal status and tumor size (P > 0.05). Estrogen is a crucial mitogen exerting its activ- ity by binding to the corresponding receptors and these have been shown to be present in 50-80% of breast ...
8
Original Article Diagnostic and prognostic value of retraction phenomenon observed in 3D ultrasonography of breast masses
... node status, and clinical biomarkers such as the estrogen receptor (ER), pro- gesterone receptor (PR), human epidermal growth factor 2 (CerbB-2), and Ki-67 to analyze the correlation ...
9
Centromere protein A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor positive breast cancer
... nodal status as categorical variables and with ESR1, CENP-A, Ki-67, and Her2/neu gene expression levels as continuous ...with ER- positive disease in the untreated TRANSBIG dataset, uni- variate analysis ...
11
Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta analysis of epidemiological studies
... Although it is well known that reproductive factors are associ- ated with breast cancer risk [1-3], it is unclear to what extent these associations differ across subtypes of breast cancer defined by estrogen ...
11
Original Article Oxidative stress pathways of flavonoid toxicity in human breast tumor cells
... example, estrogen receptor (ER) positive and negative cancers are the two most distinct breast cancer subtypes and predict the likeli- hood of benefits from antiestrogen therapy [10, ...are ...
14
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
... HER2 status; Ct: cycle threshold; ER: estrogen receptor; ESR1: estrogen receptor 1; FDA: Food and Drug Administration; FFPE: formalin-fixed paraffin-embedded; GOI: genes of ...
12
Lone
... their receptor status ...the receptor status is very important step to assess the treatment modalities as well as the prognosis of breast cancer but still this facility is not available at a ...
5
Comparative study of ER status in premenopausal and postmenopausal women with carcinoma breast
... of Estrogen Receptor Status in Premenopausal and Postmenopausal women with Carcinoma Breast” at the Department of Surgery, Government Rajaji Hospital, Madurai ,under the guidance of ...
105
Estrogen receptor (ER) was regulated by RNPC1 stabilizing mRNA in ER positive breast cancer
... of estrogen, ERα can react to DNA regulatory elements and activate or repress its target genes expression ...N-terminal estrogen-independent and C-terminal estrogen-dependent transactivation function ...
15
A phase plane graph based model of the ovulatory cycle lacking the "positive feedback" phenomenon
... It is well recognized that the “ male ” hypothalamus is not able to generate ovulatory FSH and LH surges. Here presented interpretation proposes that the “female” hypothal- amus is programed to act in two distinct modes ...
15
Kinase mediated regulation of common transcription factors accounts for the bone protective effects of sex steroids
... the estrogen receptor (ER) or andro- gen receptor (AR), which does not affect classical transcription, reverses bone loss in ovariectomized females or orchidectomized males without affecting ...
15
Epigenetic biomarker screening by FLIM-FRET for combination therapy in ER+ breast cancer
... regulate ER-responsive gene via different mechanisms. Tamoxifen binds to ER and thus inhibits ER-DNA activity [7] whereas anacardic acid disrupts H4K12ac-ERE associ- ...with ER+ breast cancers ...
9
Impaired redox regulation of estrogen metabolizing proteins is important determinant of human breast cancers
... of estrogen are mediated through ligand activated transcription factors, estrogen recep- tors (ERα and ERß) ...of estrogen action, the direct genomic pathway where E2-ER binds to ...
13
Growth factor activation of the estrogen receptor in vascular cells occurs via a mitogen activated protein kinase independent pathway
... the ER we observe in vascular cells might be due to activation of AF-1 via the MAPK ...factor–induced ER a activation; (ii) the s118a mutant ER is activatable, and (iii) overexpression of MAPKK ...
12
ER-α36: a novel biomarker and potential therapeutic target in breast cancer
... that ER- α 36- positive breast cancers tend to have more lymph node metas- tasis, advanced degree, less sensitivity to chemotherapy or endocrine therapy, and poorer outcome than ER- α 36-negative breast ...
9